The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks

Schröder, Fritz H.

doi:10.1159/000052340

European Urology

1999

DOI: 10.1159/000052340

|View full text |Cite

The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks

Fritz H. Schröder¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Sex or survival

Wilke

Krahn

Tomlinson

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Combined long-term androgen deprivation (LTAD) and radiation conveys a prostate cancer-specific survival advantage over combined short-term androgen deprivation (STAD) and radiation. The seminal question is whether or not the gains are worth the adverse effects of LTAD with respect to patient preferences. METHODS: Preferences for LTAD compared with STAD were elicited by direct patient interview using the probability trade-off method. ''Time trade-off utilities'' (TTOu) for erectile dysfunction and osteoporosis were elicited using the time tradeoff method. Participants' current prostate cancer-specific health state was assessed using the Patient-Oriented Prostate Utility Scale-Psychometric. Participants' current sexual function was assessed using the International Index of Erectile Function (IIEF). RESULTS: All participants were willing to trade survival rather than undergo LTAD compared with STAD. The mean minimally required increment in prostate cancer-specific survival (MRIS) was 8.2%. The mean TTOu for impotence was 0.78, and the mean TTOu for osteoporosis was 0.71. The MRIS was correlated with the Sexual Desire domain score of the IIEF (Spearman rank-correlation coefficient, r ¼ 0.50; P<.0001). CONCLUSIONS: Patients desired more prostate cancer-specific survival than what was afforded by LTAD and radiotherapy compared with STAD and radiotherapy.

show abstract

Sex or survival

Wilke

Krahn

Tomlinson

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks

Cited by 1 publication

References 15 publications

Sex or survival

Sex or survival

Contact Info

Product

Resources

About